

# Shaking Things Up:

## Recognizing and Managing Parkinson's Plus Syndromes


Leah Nemiroff, MSc, MMEd, MD, FRCPC

Division of Geriatric Medicine

Sept 25, 2025

# Outline + Objectives

- Case
- Introduction to parkinsonism
- Parkinson's Plus Sx
- Management considerations
- Summary



# Why this matters

- More than 110,000 Canadians > 40 live with parkinsonism
  - 10-15% are Parkinson's Plus syndromes
- Often misdiagnosed as iPD
  - Different natural histories/progression
    - Confusing & distressing for patients and caregivers
  - Risk of ineffective/harmful medications
  - More accurate diagnosis helps guide supports and interdisciplinary management

# Case

78M, frequent falls, apathy, visual hallucinations, Capgras, forgetful, can't use the TV remote, moving "slow" + gets "stuck" walking, hard to get out of a chair or turn over in bed, severity of symptoms fluctuate

**PMHx:** constipation, sleep disturbance x 10 years (spouse now in a different bedroom), HTN (diet)


No medications

## **On exam:**

- Increased tone in his upper extremities bilaterally
- Movements are slow (eg. finger tapping)
- Very unstable sit -> stand

# Parkinsonism

## TRAP Physical Manifestations of Parkinsonism




# Causes of Parkinsonism

- iPD
- **Parkinson's Plus: PSP, MSA, CBD, LBD**
- Vascular
- CTE
- Advanced dementia
- Infectious (prion dz, encephalitis etc)
- Structural (tumour, AVM, SDH, NPH)
- Metabolic (cirrhosis, Wilson's)
- Meds:
  - Eg. Anti-psychotics (e.g. haldol, phenothiazines)
- Toxins: manganese dust, cyanide, severe CO poisoning

# Parkinson's Plus Sx

- All are progressive neurodegenerative diseases
- All have some features of parkinsonism and cognitive impairment
- Comparatively rapid progression compared to idiopathic Parkinson's disease
- Poor response to levodopa (main iPD medication)


# Dementias with early parkinsonism



Spreading alpha-synucleins cause motor dysfunction and neuronal death



# Taupathies




# PSP

**Onset:** late 50s-60s, avg 65

## **Clinical Manifestations:**

- Early and frequent falls, often backward
- Vertical gaze palsy (especially downgaze), PSP “stare”
- Axial rigidity > limb rigidity
- Dysarthria, dysphagia
- Executive dysfunction, apathy, emotional lability




## Physical Exam Findings:

- Impaired voluntary vertical downgaze
  - **+LR 60 for PSP**
- Square wave jerks
- Broad-based, stiff gait with postural instability
- Surprised facial expression, decreased blink rate
- Retrocollis (neck extension/hypertonia)

**Genetic testing?** Sporadic, no readily available testing

# PSP on MRI – Hummingbird Sign



**Onset:** often earlier onset, 50s-70s, avg 60-64

**Clinical Manifestations:**

- Asymmetric parkinsonism, dystonia, myoclonus
- Executive dysfunction, apraxia
- Alien limb
- Aphasia (nonfluent/agrammatic)

## Physical Exam Findings:

- Asymmetric rigidity and bradykinesia
- Limb apraxia: difficulty performing learned tasks
- Cortical sensory loss: astereognosis, agraphesthesia
- Alien limb movements
- Dystonic limb posturing



ASTEREOGNOSIS




AGRAPHESTHESIA

MRI findings: asymmetric cortical atrophy

**Genetic testing?** Sporadic, no readily available testing

# Synucleinopathies





# MSA

**Onset:** Young, 50s-60s (avg 54) w/ early onset version < 40

## **Clinical/Physical Manifestations:**

- Progressive cognitive decline, no hallucinations
- Variable degree of parkinsonism (MSA-P)
- Rare to have tremor
- Cerebellar ataxia (MSA-C)
- **Progressive autonomic dysfunction**
  - Severe OH, sBP supine 140 – drops to sBP 60 standing after 3 minutes
  - Urinary incontinence
- Falls falls falls
- Not persistently dopamine responsive

**Genetic testing?** Usually sporadic, rare family clusters

# Hot cross bun sign (pons) on MRI



# LBD

- Fairly common (10-30% of cases)
- **Onset:** 50-85, avg 70s
- **Clinical Manifestations:**
  - Visual hallucinations
  - REM behavioural sleep disorder
  - Fluctuating cognition
  - VERY sensitive to anti-psychotics

- **Physical Exam Findings:**
  - Often rigidity and bradykinesia (less often tremor)
- Overlap with PD but presents with cog/neuropsych before or w/in 1 yr of parkinsonism
- **Genetic testing?** Overlaps with PD risk alleles (SNCA, GBA, APOE variants). Can get medical genetics referral for PD.

# Summary of Sx Features

| Feature               | LBD                                   | MSA                   | PSP                            | CBD                 |
|-----------------------|---------------------------------------|-----------------------|--------------------------------|---------------------|
| <b>Early falls</b>    | Less typical                          | Yes                   | Very early, backward           | Sometimes           |
| <b>EOM</b>            | Preserved                             | Preserved             | Vertical palsy                 | Usually normal      |
| <b>Hallucinations</b> | Common                                | Rare                  | Rare                           | Rare                |
| <b>Autonomic</b>      | Possible                              | Severe, early         | Mild                           | Rare                |
| <b>Symmetry</b>       | Symmetric                             | Symmetric             | Symmetric                      | Markedly asymmetric |
| <b>Levodopa</b>       | Minimal                               | Minimal               | Minimal, sometimes worth a try | Minimal             |
| <b>Unique feature</b> | Cognitive fluctuation, hallucinations | Autonomic dysfunction | Vertical gaze palsy            | Alien limb, apraxia |

# Management



# Dopaminergic medications

- Motor: Levodopa is mainstay of treatment for iPD

Table 1. FDA-Approved Medications to Treat Symptoms of Parkinson's Disease

| Drug Class          | Drug Name   |
|---------------------|---|
| Dopamine precursors | Levodopa  |
| Dopamine agonists   | Pramipexole, ropinirole, bromocriptine, pergolide, <sup>a</sup> cabergoline, apomorphine, lisuride, piribedil |
| COMT inhibitors     | Entacapone, tolcapone   |
| MAO-B inhibitors    | Selegiline, rasagiline  |
| Anticholinergics    | Benzotropine, trihexyphenidyl, biperiden  |
| Other               | Amantadine  |

Abbreviations: COMT, catechol-o-methyltransferase; FDA, US Food and Drug Administration; MAO-B, monoamine oxidase isoenzyme type B.  
<sup>a</sup>Voluntary US/worldwide market withdrawal in March 2007 due to safety concerns.

**COMT inh** = prolong effect of levodopa, try to reduce “off” effect

**Amantadine** (glutamate pathway) = tremor, reduce dyskinesias

**MAO-B inh** = stops breakdown of dopamine, can help reduce “offs”

**Anticholinergics** = tremor, reduce dystonias (++ SE)

# SE of PD meds

- Dyskinesias
- Multiple SE, can exacerbate:
  - Cognitive impairment
  - Neuropsych symptoms
    - Impulse control d/o (gambling, compulsive shopping, hypersexuality, compulsive eating)
  - Orthostatic HypoTN
  - Daytime somnolence, sleep attacks, nausea, malaise, peripheral edema, etc.



|   | Evidence in dementia with Lewy bodies | Evidence in Parkinson's disease dementia | Comments  |
|---|---------------------------------------|--|---|
| <b>Cognition</b>  |                                       |  |   |
| Acetylcholinesterase inhibitors   | Efficacious                           | Efficacious                              | Rivastigmine and donepezil class 1 efficacy in dementia with Lewy bodies; Cochrane review of dementia with Lewy bodies, Parkinson's disease dementia, and MCI-PD showed overall positive effect |
| Memantine   | Insufficient evidence                 | Insufficient evidence                    | Small significant improvement in overall clinical impression  |
| <b>Parkinsonism</b>   |                                       |  |   |
| Levodopa  | Insufficient evidence                 | Insufficient evidence                    | Levodopa replacement less effective in dementia with Lewy bodies than in Parkinson's disease; probable increased risk of psychosis in patients with dementia with Lewy bodies                   |
| <b>Hallucinations</b>   |                                       |  |   |
| Acetylcholinesterase inhibitors   | Insufficient evidence                 | Insufficient evidence                    | No randomised controlled trials have assessed hallucinations; other evidence is positive  |
| Antipsychotic drugs   | Unlikely to be efficacious            | Mixed                                    | In treatment of psychosis associated with Parkinson's disease and Parkinson's disease dementia, clozapine is effective and olanzapine ineffective; the evidence for quetiapine is mixed         |
| <b>Depression or anxiety</b>  |                                       |  |   |
| Antidepressant drugs  | Insufficient evidence                 | Insufficient evidence                    | Evidence mixed; some beneficial effect with venlafaxine, paroxetine, and nortriptyline in Parkinson's disease   |
| <b>RBD</b>  |                                       |  |   |
| Melatonin   | Insufficient evidence                 | Insufficient evidence                    | Evidence in Parkinson's disease from non-randomised trials  |
| Clonazepam  | Insufficient evidence                 | Insufficient evidence                    | Non-randomised controlled trial evidence positive   |
| <b>Excessive daytime sleepiness</b>   |                                       |  |   |
| Modafinil   | Insufficient evidence                 | Insufficient evidence                    | Evidence in Parkinson's disease from randomised controlled trials; non-randomised trial evidence in dementia with Lewy bodies   |
| <b>Urinary symptoms</b>   |                                       |  |   |
| Trospium  | Insufficient evidence                 | Insufficient evidence                    | No randomised controlled trials reported but does not cross blood-brain barrier so in theory should be preferable to oxybutynin   |
| <b>Postural hypotension</b>   |                                       |  |   |
| Fludrocortisone   | Insufficient evidence                 | Insufficient evidence                    | No evidence from randomised controlled trials, but other evidence positive in both Parkinson's disease dementia and dementia with Lewy bodies   |
| MCI-PD=mild cognitive impairment in Parkinson's disease. RBD=rapid eye movement sleep behaviour disorder.               |                                       |  |   |
| <b>Table 2: Evidence for treatment of dementia with Lewy bodies and Parkinson's disease dementia</b> <sup>125,130</sup> |                                       |  |   |

# What if not clear?

Sometimes it is extremely challenging to decide if someone has **iPD vs PSP vs MSA vs LBD vs mixed vs other**

- Especially if you are seeing them late in the disease course
  - E.g. marked postural hypoTN common later in PD, happens much earlier in MSA
- Sinemet trial (dopamine) can be helpful
  - We get pre and post PT measures (TUG, BERG)
  - Try to get to at least 600mg levodopa daily

# Treatment of other sx

- Orthostasis:
  - Hydration + salt, compression stockings (up to abdomen)
  - Fludrocortisone, midodrine
  - Non-pharm strategies: slow position changes
- REM:
  - high dose melatonin can be transformative
  - If distressing + melatonin ineffective, trial lowest dose clonazepam at bedtime
- Mood sx: SSRIs +/- CBT if cogn able
- Hallucinations: quetiapine best worst option

# Treatment of other sx

- Dementia:
  - Evidence for cholinesterase inhibitors in LBD

| Name         | Mechanism  | Half-life |
|--------------|--|-----------|
| Donepezil    | Acetylcholine inhibitor                              | 70 hours  |
| Galantamine  | Acetylcholine inhibitor                              | 7 hours   |
| Rivastigmine | Dual acetylcholine & butyrylcholinesterase inhibitor | 1 hour    |

# Note: cholinesterase inhibitors

LBD: can have impressive impact on hallucinations, delusions, and behavioural symptoms

- Can also reduce intensity and frequency of fluctuations
- Some studies suggest a better cognitive response than AD
- Often a robust initial response
- Will eventually stop responding as disease progresses

# Non pharmacologic management

## Cornerstone of care!

- **PT:** balance and falls prevention, maintenance of strength/endurance, ROM/spasticity in CBD
- **OT:** functional optimization, gait and adaptive aids, home safety/equipment
- **SLP:** dysphagia and dysarthria support
- **RT:** strategies for patient & caregiver
- **SW:** help with accessing resources
- **Dietician:** intake/nutrition  
and more!



# Back to the case

78M, frequent falls, apathy, visual hallucinations, Capgras, forgetful, can't use the TV remote, moving "slow" + gets "stuck" walking, hard to get out of a chair or turn over in bed, severity of symptoms fluctuate

- Started with hallucinations, cogn 2 years ago, now bradykinesia and rigidity on exam
- Dx LBD
- Rx rivastigmine 1.5mg BID, increase to 3mg BID in 4 weeks -> Capgras resolves!

# Take Home Points

1. Suspect Parkinson's Plus when:
  - Poor levodopa response
  - Early falls
  - Early hallucinations
  - Early severe autonomic dysfunction
  - Atypical features (EOM, alien limb)
2. Mostly clinical diagnoses with some MRI findings, no routine genetic testing available/helpful
3. Trial of cholinesterase inhibitors can be considered in LBD, minimal to no role for levodopa
4. Supportive, interdisciplinary care is key to person-centered care



# Thank you!

## Questions, discussion?